Laden…
2-(4-hydroxy-2-oxopyrrolidin-1-yl)acetamide
Oxiracetam is a nootropic from the racetam family, primarily investigated for its potential to enhance cognitive functions such as memory and learning ability. It mainly acts through the modulation of AMPA receptors and the promotion of acetylcholine release, supporting synaptic plasticity. The substance is considered well-tolerated with a low risk of adverse effects. Clinical studies are addressing its potential in neurodegenerative diseases.
Class
Racetam
Pharmacological context
Mechanism
Oxiracetam wirkt als Modulator der AMPA- und NMDA-Rezeptoren, was zu...
Short read on known pharmacology
Interactions
No curated pairs visible
Curated visible combinations
Risk theme
Interpret risks carefully
Condensed from structured notes
Receptor Targets
Mechanism of Action
Designations
IUPAC: 2-(4-hydroxy-2-keto-pyrrolidino)acetamide
Legal Status
Legal status not verified by official sources. Please check current legislation independently.
Information without guarantee. Not legal advice.
Receptor Profile
Der NMDA-Rezeptor ist ein ionotroper Glutamatrezeptor, der eine zentrale Rolle bei synaptischer Plastizität, Lernen und Gedächtnisbildung spielt. Er benötigt sowohl Glutamat als auch Glycin als Co-Agonisten zur Aktivierung.
Der 5-HT2A-Rezeptor ist ein Serotonin-Rezeptor der Klasse Gq-gekoppelter GPCRs. Er ist der primäre molekulare Angriffspunkt klassischer Psychedelika und spielt eine Rolle bei Kognition und Wahrnehmung.
Der Dopamintransporter (DAT) ist ein Natrium-abhängiger Monoamintransporter, der Dopamin aus dem synaptischen Spalt entfernt. Er ist ein zentrales Ziel von Stimulants und spielt eine Schlüsselrolle im Belohnungssystem.
Der AMPA-Rezeptor ist ein ionotroper Glutamatrezeptor, der die schnelle exzitatorische synaptische Übertragung im ZNS vermittelt. Er arbeitet eng mit NMDA-Rezeptoren bei der synaptischen Plastizität zusammen.
Synapedia Evidence
Effects & Pharmacology is partially translated. Some details are still being expanded.
Oxiracetam wirkt als Modulator der AMPA- und NMDA-Rezeptoren, was zu einer Verbesserung der synaptischen Übertragung und kognitiven Funktionen führt.
Known Effects
Individual effects may vary significantly. These are pharmacologically documented effects.
Reported range 600 mg
Total duration 6–8 hours
Oral
| Tier | Dosage |
|---|---|
| Light | 300 mg |
| Reported | 600 mg |
| Strong | 1200 mg |
Oral
Onset
1–2 hours
Peak
2–4 hours
Total duration
6–8 hours
After effects
2–4 hours
Avoid uncertain dosage claims and do not infer numbers when data is unclear.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, combinations, and pre-existing conditions significantly affect outcomes. These figures are not dosing recommendations — they describe reported ranges, not safe amounts.
Risks
Summary
Die Sicherheit und Langzeitwirkungen sind nicht umfassend erforscht.
Safer Use
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Interaction details from the knowledge layer are still being translated.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
The signal hub collects approved risk signals, experience reports and source leads by relevance.